Sonoma Pharmaceuticals (NASDAQ:SNOA) soared Friday after announcing Thursday evening a new application for its intraoperative pulse lavage irrigation treatment that could replace IV bags in some surgical procedures. Sonoma said the treatment will be available in Europe this year and in the U.S. commercially in 2024.
The company, based in Boulder, Colorado, developed this new application of its wound care technology in response to an unmet need for a non-toxic irrigation solution that can prevent infection and improve healing time. The intraoperative pulse lavage container is designed to be used in combination with a pulse lavage irrigation device, or flush gun, for abdominal, laparoscopic, orthopedic, and periprosthetic procedures.
This product replaces commonly used non-antimicrobial saline and aggressive rinsing solutions with safe and effective Microcyn Technology. Microcyn Technology assists in the reduction of microorganisms, is non-toxic, and has regenerative properties, making it critical in preventing infection and promoting wound healing. Sonoma's pulse lavage container is also cost competitive with IV bags, the current standard of care.
Sonoma developed the intraoperative pulse lavage irrigation treatment in close collaboration with the medical community and Sonoma's existing distribution partners in Europe and expects this new application will be met with wide acceptance. Sonoma is now accepting orders for the pulse lavage irrigation treatment solution, which is expected to be ready for commercial use in Europe in September 2023. Sonoma anticipates commercial launch in the U.S. in 2024.
SNOA shares spiked 36 cents, or 39.6%, soon after Friday’s opening to $1.34.
